ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near Madrid, MD, ESP:

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 105 other locations

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Madrid, Spain and 48 other locations

objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...

Enrolling
CLL
Drug: Zanubrutinib
Drug: Sonrotoclax

Phase 3

BeiGene
BeiGene

Madrid, Spain and 81 other locations

together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Esca...

Active, not recruiting
Chronic Lymphocytic Leukemia
Lymphoma, Non-Hodgkin
Drug: JNJ-67856633
Drug: JNJ-64264681

Phase 1

Janssen (J&J Innovative Medicine)

Madrid, Spain and 27 other locations

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

Phase 2

Janssen (J&J Innovative Medicine)

Madrid, Spain and 37 other locations

with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Obinutuzumab

Phase 1

Celgene
Celgene

Madrid, Spain and 14 other locations

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Madrid, Spain and 130 other locations

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Madrid, Madrid, Comunidad De, Spain and 145 other locations

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...

Enrolling
Chronic Lymphocytic Leukemia
Hypogammaglobulinemia
Biological: Panzyga
Other: Placebo

Phase 3

Octapharma

Madrid, Spain and 82 other locations

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Madrid, Spain and 179 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems